Navigation Links
NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference
Date:9/2/2008

SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Alex Lukianov, Chairman and Chief Executive Officer, and Kevin O'Boyle, Executive Vice President and Chief Financial Officer, are scheduled to present at the Morgan Stanley Global Healthcare Unplugged Conference at the Grand Hyatt New York Hotel on Tuesday, September 9, 2008, at 8:35 a.m. ET.

A live Web cast of the presentation will be available online from the investor relations page of the Company's corporate Web site at http://www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, http://www.nuvasive.com, for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Contact:

Kevin C. O'Boyle

EVP & Chief Financial Officer

NuVasive, Inc.

858-909-1800

investorrelations@nuvasive.com

Investors:

Nick Laudico/Zack Kubow

The Ruth Group

646-536-7030/7020

nlaudico@theruthgroup.com

zkubow@theruthgroup.com

Media:

Jason Rando

The Ruth Group

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NuVasive Completes Acquisition of Osteocel Biologics Business
2. NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results
3. NuVasive to Present at William Blair 28th Annual Growth Stock Conference
4. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
5. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
6. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
7. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
8. NuVasive to Host Investor Reception on September 11, 2007
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Conference
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... New Canaan, CT (PRWEB) , ... March 29, 2017 , ... ... of antibiotics and hormones in the world’s food supply through enhancement of the gut ... in the round included Connecticut Innovations , New York-based Sustainable Income Capital Management, ...
(Date:3/29/2017)... GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company") announced today ... test for breast cancer, via its Virginia ... a blood-based biomarker test with a sophisticated algorithm to determine ... ... BreastSentry measures the fasting plasma levels of two biomarkers in ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... replace paper-based processes and enhance training plan management for consistent implementation of standards ... partner with the SHL Group to help improve and streamline their training and ...
(Date:3/28/2017)... Michigan (PRWEB) , ... March 28, 2017 , ... ... awarded a Phase II Small Business Innovation Research (SBIR) grant from the National ... approximately $750,000 over two years to develop a suite of BioGel™ biopolymer materials ...
Breaking Biology Technology:
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScan® technology provides the fastest and most ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):